Press for Actavis
Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).
Actavis has indicated its commitment to growing OTC markets, with investment in two of its 17 brands. The manufacturer, better known for its generics business, last week announced advertising campaigns for sleep aid Sominex and cystitis brand Cymalon.
Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg. Distribution of the product will commence immediately.
Iceland's Actavis Group didn't succeed in its bid to buy the German generics maker Ratiopharm, but it has nabbed the company's former chief executive. Actavis has chosen the ex-chief of Ratiopharm, Claudio Albrecht, as its own new CEO.